Servier’s decision to exit a Parkinson’s disease pact has triggered belt tightening at French biotech Oncodesign Precision Medicine. | Servier’s decision to exit a Parkinson’s disease pact has ...

MOMA Therapeutics, a clinical-stage biopharmaceutical company discovering and developing a new generation of precision ...

Andrew Mackinnon, Executive GM, Medable, explains how the company’s recent approval in France could support the expansion of ...

Plus, news about Cen­tu­ry Ther­a­peu­tics, Ake­bia Ther­a­peu­tics, Eye­n­ovia, Be­taliq, Alvotech, Genen­ta Sci­ence, Aa­di Bio­science, and Ex­i­cure: ...

It follows a study by the EU drugs agency. It is the largest European project monitoring illegal drug use through wastewater and saw sewage samples from 26 countries analysed over one week.

Further research revealed that one of these drugs, DDL-920 – developed at UCLA, led to the complete recovery of movement control – something many stroke patients never regain.

Some countries will also use IRP to help determine the eligibility of certain products for reimbursement. There is a growing awareness, however, of the repercussions of IRP, including drug shortages, ...

As such, Servier is focusing on a limited number of neurodegenerative diseases where accurate patient profiling makes it possible to offer a targeted therapeutic response through precision medicine.

Black Di­a­mond Ther­a­peu­tics has found a buy­er for an ear­ly-stage tar­get­ed can­cer drug, which was brushed to the side last year as it fo­cused re­sources … ...

Servier will lead the development activities ... Also Read: Black Diamond Therapeutics’ Lead Drug Candidate Shows Initial Anti-Tumor Activity In Certain Type Of Lung Cancer Resistant To ...

the biotech has licensed the RAF inhibitor to Servier for $70 million upfront and up to $710 million in milestones. In October, Black Diamond concluded its attempt to push two cancer drugs through ...